Titre : Maladie des légionnaires

Maladie des légionnaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Scleroderma, Systemic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Maladie des légionnaires : Questions médicales les plus fréquentes", "headline": "Maladie des légionnaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Maladie des légionnaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Maladie des légionnaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Légionellose", "url": "https://questionsmedicales.fr/mesh/D007876", "about": { "@type": "MedicalCondition", "name": "Légionellose", "code": { "@type": "MedicalCode", "code": "D007876", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C08.730.382" } } }, "about": { "@type": "MedicalCondition", "name": "Maladie des légionnaires", "alternateName": "Legionnaires' Disease", "code": { "@type": "MedicalCode", "code": "D007877", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sophie Jarraud", "url": "https://questionsmedicales.fr/author/Sophie%20Jarraud", "affiliation": { "@type": "Organization", "name": "Institut des Agents Infectieux, Centre National de Référence des Légionelles, Hospices Civils de Lyon, Lyon, France. sophie.jarraud@univ-lyon1.fr." } }, { "@type": "Person", "name": "Chris Edens", "url": "https://questionsmedicales.fr/author/Chris%20Edens", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christophe Ginevra", "url": "https://questionsmedicales.fr/author/Christophe%20Ginevra", "affiliation": { "@type": "Organization", "name": "The National Reference Center of Legionella, 69317 Lyon, France." } }, { "@type": "Person", "name": "Lara Payne Hallström", "url": "https://questionsmedicales.fr/author/Lara%20Payne%20Hallstr%C3%B6m", "affiliation": { "@type": "Organization", "name": "European Centre for Disease Prevention and Control (ECDC), Solna, Sweden." } }, { "@type": "Person", "name": "Kelsie Cassell", "url": "https://questionsmedicales.fr/author/Kelsie%20Cassell", "affiliation": { "@type": "Organization", "name": "Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.", "datePublished": "2024-08-23", "url": "https://questionsmedicales.fr/article/39273131", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms25179182" } }, { "@type": "ScholarlyArticle", "name": "Pulmonary Hypertension in Scleroderma- Evaluation and Management.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36163292", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.disamonth.2022.101468" } }, { "@type": "ScholarlyArticle", "name": "Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36244404", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.chest.2022.09.044" } }, { "@type": "ScholarlyArticle", "name": "Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35931315", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.autrev.2022.103167" } }, { "@type": "ScholarlyArticle", "name": "Scleroderma autoantibodies in guiding monitoring and treatment decisions.", "datePublished": "2022-08-29", "url": "https://questionsmedicales.fr/article/36082759", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/BOR.0000000000000904" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012140" }, { "@type": "ListItem", "position": 3, "name": "Infections de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012141" }, { "@type": "ListItem", "position": 4, "name": "Légionellose", "item": "https://questionsmedicales.fr/mesh/D007876" }, { "@type": "ListItem", "position": 5, "name": "Maladie des légionnaires", "item": "https://questionsmedicales.fr/mesh/D007877" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Maladie des légionnaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Maladie des légionnaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Maladie des légionnaires", "description": "Comment diagnostique-t-on la maladie des légionnaires ?\nQuels tests sont utilisés pour confirmer l'infection ?\nLes radiographies sont-elles utiles pour le diagnostic ?\nQuels symptômes orientent vers un diagnostic de légionellose ?\nLa biopsie pulmonaire est-elle nécessaire pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Maladie des légionnaires", "description": "Quels sont les symptômes courants de la maladie des légionnaires ?\nLa diarrhée est-elle un symptôme possible ?\nLes symptômes apparaissent-ils rapidement ?\nY a-t-il des symptômes spécifiques chez les personnes âgées ?\nLa confusion mentale est-elle un symptôme associé ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Maladie des légionnaires", "description": "Comment prévenir la maladie des légionnaires ?\nLes systèmes de climatisation doivent-ils être surveillés ?\nLes personnes à risque doivent-elles prendre des précautions ?\nLes douches peuvent-elles être une source de contamination ?\nDes vaccins existent-ils pour prévenir cette maladie ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Maladie des légionnaires", "description": "Quel est le traitement principal de la maladie des légionnaires ?\nLes corticostéroïdes sont-ils recommandés ?\nQuelle est la durée du traitement antibiotique ?\nDes soins de soutien sont-ils nécessaires ?\nLes patients doivent-ils être hospitalisés ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Maladie des légionnaires", "description": "Quelles sont les complications possibles de la légionellose ?\nLa maladie peut-elle entraîner des séquelles ?\nLes personnes âgées sont-elles plus à risque de complications ?\nComment les complications sont-elles gérées ?\nLe décès est-il possible en cas de légionellose ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Maladie des légionnaires", "description": "Quels sont les principaux facteurs de risque ?\nLes fumeurs sont-ils plus susceptibles de contracter la maladie ?\nLes personnes immunodéprimées sont-elles à risque ?\nLes voyages peuvent-ils augmenter le risque d'infection ?\nLes antécédents de pneumonie augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D007877?mesh_terms=Scleroderma,+Systemic&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la maladie des légionnaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests de culture des expectorations ou des analyses sanguines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer l'infection ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests PCR et les tests d'antigènes urinaires sont couramment utilisés." } }, { "@type": "Question", "name": "Les radiographies sont-elles utiles pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les radiographies thoraciques montrent souvent des infiltrats pulmonaires." } }, { "@type": "Question", "name": "Quels symptômes orientent vers un diagnostic de légionellose ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre élevée, toux, dyspnée et douleurs thoraciques sont des indicateurs clés." } }, { "@type": "Question", "name": "La biopsie pulmonaire est-elle nécessaire pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Rarement, elle est utilisée si les autres tests ne sont pas concluants." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la maladie des légionnaires ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, toux, essoufflement, douleurs musculaires et maux de tête sont fréquents." } }, { "@type": "Question", "name": "La diarrhée est-elle un symptôme possible ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la diarrhée peut survenir chez certains patients atteints de légionellose." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent apparaître 2 à 10 jours après l'exposition à la bactérie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques chez les personnes âgées ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées peuvent présenter des symptômes plus graves et des complications." } }, { "@type": "Question", "name": "La confusion mentale est-elle un symptôme associé ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la confusion ou des troubles neurologiques peuvent se manifester dans les cas graves." } }, { "@type": "Question", "name": "Comment prévenir la maladie des légionnaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir les systèmes d'eau propres et contrôler la température de l'eau est essentiel." } }, { "@type": "Question", "name": "Les systèmes de climatisation doivent-ils être surveillés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les systèmes de climatisation doivent être régulièrement entretenus pour éviter la contamination." } }, { "@type": "Question", "name": "Les personnes à risque doivent-elles prendre des précautions ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées et immunodéprimées doivent éviter les environnements à risque." } }, { "@type": "Question", "name": "Les douches peuvent-elles être une source de contamination ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les douches peuvent libérer des aérosols contenant la bactérie Legionella." } }, { "@type": "Question", "name": "Des vaccins existent-ils pour prévenir cette maladie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin efficace contre la maladie des légionnaires." } }, { "@type": "Question", "name": "Quel est le traitement principal de la maladie des légionnaires ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques, comme la lévofloxacine ou l'azithromycine, sont utilisés." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils recommandés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont généralement pas recommandés, sauf en cas de complications sévères." } }, { "@type": "Question", "name": "Quelle est la durée du traitement antibiotique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dure généralement 10 à 14 jours, selon la gravité de l'infection." } }, { "@type": "Question", "name": "Des soins de soutien sont-ils nécessaires ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'oxygénothérapie et l'hydratation peuvent être nécessaires pour les patients graves." } }, { "@type": "Question", "name": "Les patients doivent-ils être hospitalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité des symptômes; les cas sévères nécessitent souvent une hospitalisation." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la légionellose ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance respiratoire, le choc septique et la défaillance multiviscérale." } }, { "@type": "Question", "name": "La maladie peut-elle entraîner des séquelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent avoir des séquelles pulmonaires à long terme." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque de complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru de complications graves et de mortalité." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent des soins intensifs et un traitement symptomatique." } }, { "@type": "Question", "name": "Le décès est-il possible en cas de légionellose ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la légionellose peut être mortelle, surtout chez les personnes à risque." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge avancé, le tabagisme, et les maladies chroniques." } }, { "@type": "Question", "name": "Les fumeurs sont-ils plus susceptibles de contracter la maladie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque de développer une légionellose." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées ont un risque accru d'infection sévère." } }, { "@type": "Question", "name": "Les voyages peuvent-ils augmenter le risque d'infection ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages dans des zones avec des systèmes d'eau contaminés augmentent le risque." } }, { "@type": "Question", "name": "Les antécédents de pneumonie augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avoir des antécédents de pneumonie peut prédisposer à la légionellose." } } ] } ] }

Sources (10000 au total)

Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.

Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort.... Do enrichment strategies for progressive ILD impact efficacy, representativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?... We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II... In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529... The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitm...

Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).

Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with... Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confi... Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0... Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk....

Scleroderma autoantibodies in guiding monitoring and treatment decisions.

One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia... There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows... ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...

Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome.

The mechanisms of systemic autoimmune diseases (ADs) are still not clearly understood. Understanding the etiology of systemic ADs and identifying new therapeutic targets require a systems science appr...

Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study.

People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe... The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys... Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by... People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...

[Autoimmune and inflammatory pathologies associated with systemic scleroderma: Clinical, serological and prognostic profiles. Bi-centric retrospective series in the PACA region].

Systemic sclerosis (SSc) is a rare auto-immune disease, affecting principally women between 40 and 60 years old. It is caracterised by a cutaneous and visceral fibrosis, an alteration of the microvasc... We have analysed the data of a retrospective and bicentrique cohort, from the internal medicine unit of Hôpital Nord in Marseille and from the internal medicine unit of the Hôpital Sainte-Anne in Toul... The cohort included 151 patients including 134 limited cutaneous SSc. Fifty-two (34.4%) patients presented at least one associated auto-immune or inflammatory disease. The association of two connectiv... SSc is often associated with other autoimmune diseases. This interrelation between associated pathologies and SSc, modifying sometimes the evolution of SSc, enhances the need of a personalized follow-...

Juvenile and adult-onset scleroderma: Different clinical phenotypes.

Systemic sclerosis (SSc) represents extremely rare disease with majority of data coming from adults. Studies comparing juvenile- (jSSc) and adult-onset (aSSc) patients are limited. We aimed to compare... A retrospective study among pediatric and adult Scl patients has been performed. Demographic characteristics, clinical features, autoantibody profiles, and treatment data were retrieved from the datab... A total of 158 adults and 58 juvenile Scl patients were identified. The mean age at the disease onset was 37±14.7 vs. 8.8 ± 4.1 years, mean age at diagnosis 42±15.2 vs. 10.4 ± 3.8 years and mean follo... Juvenile and adult-onset Scl represent rarely seen conditions with different clinical phenotypes. Pediatric patients with LS are more commonly seen by pediatric rheumatologists, in contrary to adults....